SEC Form 4
Lyell Immunopharma, Inc. (LYEL) insider trading
In the 12 months to Nov 6, 2026, 2 LYEL insiders reported open-market sales of $74.5K across 3 filings; 4 insiders bought $75.0M.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $74.5K
- 3 filings · 2 insiders
- Open-market purchases
- $75.0M
- 4 filings
- Pre-arranged sales (10b5-1)
- 2 of 3
- $274 of $74.5K sold (0%)
Who traded LYEL, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
LYEL daily close from Nov 6, 2025 to Nov 6, 2026, between $7.51 and $38.60, last $15.19. 3 sale and 4 purchase filings by 6 insiders, marked at their filing dates. ARCH Venture Fund IX Overage, L.P., 10% owner: bought $25.0M across 1 filing, first filed Nov 5, 2026, last Nov 5, 2026. Robert Nelsen, 10% owner: bought $25.0M across 1 filing, first filed Nov 5, 2026, last Nov 5, 2026. ARCH Venture Fund IX, L.P., 10% owner: bought $12.5M across 1 filing, first filed Mar 9, 2026, last Mar 9, 2026. Kristina Burow, 10% owner: bought $12.5M across 1 filing, first filed Mar 9, 2026, last Mar 9, 2026. Veronica Sanchez Bulis, VP, Corporate Controller: sold $74.2K across 1 filing, first filed Jan 6, 2026, last Jan 6, 2026. Innovative Cellular Therapeutics Holdings Ltd, 10% owner: sold $274 across 2 filings, first filed Jul 17, 2026, last Jul 20, 2026.
Largest mark · tap a row for others
ARCH Venture Fund IX Overage, L.P. · 10% owner
Purchase $24,999,992
2,321,262 shares at $10.77 avg
Filed Nov 5, 2026 · traded Nov 4
Close on filing date $15.00
ARCH Venture Fund IX Overage, L.P. · 10% owner
10% owner
$25.0M boughtRobert Nelsen · 10% owner
10% owner
$25.0M boughtARCH Venture Fund IX, L.P. · 10% owner
10% owner
$12.5M boughtKristina Burow · 10% owner
10% owner
$12.5M boughtVeronica Sanchez Bulis · VP, Corporate Controller
VP, Corporate Controller
$74.2K soldInnovative Cellular Therapeutics Holdings Ltd · 10% owner
10% owner
$274 soldOpen-market trades
7 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| ARCH Venture Fund IX Overage, L.P. | 10% owner | — | $25.0M | 1 | — | |
| Robert Nelsen | 10% owner | — | $25.0M | 1 | — | |
| ARCH Venture Fund IX, L.P. | 10% owner | — | $12.5M | 1 | — | |
| Kristina Burow | 10% owner | — | $12.5M | 1 | — | |
| Veronica Sanchez Bulis | VP, Corporate Controller | $74.2K | — | 1 | — | |
| Innovative Cellular Therapeutics Holdings Ltd | 10% owner | $274 | — | 2 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Robert Nelsen 10% owner | Purchase | 2,321,262 | $10.77 | $25.0M | 3,747,790 | |
traded | ARCH Venture Fund IX Overage, L.P. 10% owner | Purchase | 2,321,262 | $10.77 | $25.0M | 3,747,790 | |
traded | Innovative Cellular Therapeutics Holdings Ltd 10% owner | SalePre-arranged (10b5-1) | 10 | $13.70 | $137 | 2,857,480 | |
traded | Innovative Cellular Therapeutics Holdings Ltd 10% owner | SalePre-arranged (10b5-1) | 10 | $13.73 | $137 | 2,857,490 | |
traded | Kristina Burow 10% owner | Purchase | 488,090 | $25.61 | $12.5M | 1,426,528 | |
traded | ARCH Venture Fund IX, L.P. 10% owner | Purchase | 488,090 | $25.61 | $12.5M | 1,426,528 | |
traded | Veronica Sanchez Bulis VP, Corporate Controller | Sale | 2,072 | $35.80 | $74.2K | 7,141 |
GET /stocks/filings/vX/form-4?tickers=LYEL&filing_date.gte=2025-11-06&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"LYEL"
],
"issuer_cik": "0001806952",
"owner_cik": "0002016083",
"accession_number": "0001012975-26-001013",
"form_type": "4",
"filing_date": "2026-11-05",
"period_of_report": "2026-11-04",
"issuer_name": "Lyell Immunopharma, Inc.",
"issuer_trading_symbol": "LYEL",
"owner_name": "ARCH Venture Partners XIII, L.P.",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-11-04",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 2321262,
"transaction_price_per_share": 10.77,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 3747790,
"transaction_value": 24999991.74,
"direct_or_indirect": "I",
"nature_of_ownership": "See Footnote",
"footnotes": [
{
"id": "F1",
"description": "These shares were purchased on November 4, 2026 pursuant to a securities purchase agreement dated November 3, 2026 at a price per share of $10.77."
},
{
"id": "F2",
"description": "These shares are directly held by ARCH Venture Fund XIII, L.P. (\"ARCH XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\") is the general partner of AVP XIII LP. Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the \"AVP XIII LLC Committee Members\"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."
}
],
"remarks": "This Form 4 is one of two reports relating to the same transaction being filed jointly by ARCH Venture Partners XIII, LLC, ARCH Venture Partners XIII, L.P., ARCH Venture Fund XIII, L.P., Keith Crandell, Robert Nelsen, Kristina Burow, Steven Gillis, Paul Berns, Clinton Bybee, ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P. and ARCH Venture Fund IX Overage, L.P."
},
{
"tickers": [
"LYEL"
],
"issuer_cik": "0001806952",
"owner_cik": "0001219042",
"accession_number": "0001012975-26-001013",
"form_type": "4",
"filing_date": "2026-11-05",
"period_of_report": "2026-11-04",
"issuer_name": "Lyell Immunopharma, Inc.",
"issuer_trading_symbol": "LYEL",
"owner_name": "NELSEN ROBERT",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-11-04",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 2321262,
"transaction_price_per_share": 10.77,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 3747790,
"transaction_value": 24999991.74,
"direct_or_indirect": "I",
"nature_of_ownership": "See Footnote",
"footnotes": [
{
"id": "F1",
"description": "These shares were purchased on November 4, 2026 pursuant to a securities purchase agreement dated November 3, 2026 at a price per share of $10.77."
},
{
"id": "F2",
"description": "These shares are directly held by ARCH Venture Fund XIII, L.P. (\"ARCH XIII\"). ARCH Venture Partners XIII, L.P. (\"AVP XIII LP\") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC (\"AVP XIII LLC\") is the general partner of AVP XIII LP. Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the \"AVP XIII LLC Committee Members\"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any."
}
],
"remarks": "This Form 4 is one of two reports relating to the same transaction being filed jointly by ARCH Venture Partners XIII, LLC, ARCH Venture Partners XIII, L.P., ARCH Venture Fund XIII, L.P., Keith Crandell, Robert Nelsen, Kristina Burow, Steven Gillis, Paul Berns, Clinton Bybee, ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P. and ARCH Venture Fund IX Overage, L.P."
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 33 records
- Tax withholding (sold to cover)25 records
- Grants and awards4 records
- Other4 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has Lyell Immunopharma, Inc.'s CEO sold stock?
No. Lynn Seely (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is LYEL’s insider data?
These are LYEL Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track LYEL insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for LYEL every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.